| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 05/17/2001 | WO2001022955A3 Novel combination of loteprednol and antihistamines |
| 05/17/2001 | WO2001012598A9 METHODS OF INHIBITING BINDING OF β-SHEET FIBRIL TO RAGE AND CONSEQUENCES THEREOF |
| 05/17/2001 | WO2001007471A9 Cell cycle and proliferation proteins |
| 05/17/2001 | WO2000076550A3 Carrier-drug conjugate |
| 05/17/2001 | WO2000049137B1 Pluripotential cell derived from an embryonic stem cell and a nucleus of a somatic cell |
| 05/17/2001 | WO2000030671A9 Nf-at mediates cardiac hypertrophy, methods and reagents related thereto |
| 05/17/2001 | WO1999044620A9 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 05/17/2001 | DE19954707A1 Imidazolverbindungen als Phosphodiesterase VII-Hemmer Imidazole compounds as phosphodiesterase VII inhibitor |
| 05/17/2001 | DE19954516A1 Epinastin-haltige Lösungen Epinastine-containing solutions |
| 05/17/2001 | DE19954514A1 Manipulating activity of cells ex vivo, useful e.g. in immunotherapy of cancer or viral infection, by treating the cells with antigens, adjuvants and stimulants |
| 05/17/2001 | DE19953899A1 Carboxamid-substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel Carboxamide-substituted benzimidazole derivatives, processes for their preparation and their use as medicaments |
| 05/17/2001 | DE10044129A1 New autogenous vaccine useful in the treatment of autoimmune and allergic diseases |
| 05/17/2001 | CA2404763A1 Mutated il-13 molecules and their uses |
| 05/17/2001 | CA2391421A1 Compositions and methods for modifying an immune response against tropomyosin |
| 05/17/2001 | CA2391299A1 Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors |
| 05/17/2001 | CA2390999A1 Induction of mucosal immunity by vaccination via the skin route |
| 05/17/2001 | CA2390919A1 Nose drop containing condensed pyridazine |
| 05/17/2001 | CA2390655A1 Compositions and methods for treatment of neurological disorders and neurodegenerative diseases |
| 05/17/2001 | CA2390613A1 Vaccines for mycoplasma bovis and methods of use |
| 05/17/2001 | CA2390438A1 19 human secreted proteins |
| 05/17/2001 | CA2390421A1 24 human secreted proteins |
| 05/17/2001 | CA2390163A1 Dye labeled imidazoquinoline compounds |
| 05/17/2001 | CA2389724A1 28 human secreted proteins |
| 05/17/2001 | CA2389722A1 15 human secreted proteins |
| 05/17/2001 | CA2389392A1 A method for treating viral diseases and other disorders by altering immediate gene expression through administration of peptide t |
| 05/17/2001 | CA2389330A1 Kringle domain-containing polynucleotides, polypeptides, and antibodies |
| 05/17/2001 | CA2389326A1 35 human secreted proteins |
| 05/17/2001 | CA2389204A1 Protein present at the surface of hematopoietic stem cells of the lymphoid line and of nk cells, and uses thereof |
| 05/17/2001 | CA2388914A1 15 human secreted proteins |
| 05/17/2001 | CA2388912A1 6 human secreted proteins |
| 05/17/2001 | CA2388729A1 Imidazopyridine derivatives as phosphodiesterase vii inhibitors |
| 05/17/2001 | CA2388643A1 Use of lytic toxins and toxin conjugates |
| 05/17/2001 | CA2388008A1 29 human secreted proteins |
| 05/17/2001 | CA2387964A1 22 human secreted proteins |
| 05/17/2001 | CA2387959A1 21 human secreted proteins |
| 05/17/2001 | CA2387624A1 Pdgf receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same |
| 05/17/2001 | CA2361139A1 Substituted 2-aryl-3-(heteroaryl)-imidazo[1,2-a]pyrimidines, and related pharmaceutical compositions and methods |
| 05/16/2001 | EP1098985A1 Genes of the dead box protein family, their expression products and use |
| 05/16/2001 | EP1098910A1 Antigenic complex comprising immunostimulatory peptide, cd4, and chemokine receptor domain for hiv treatment and immune disorders |
| 05/16/2001 | EP1098909A1 Hybrid human/rodent igg antibody to cd3, and methods of its construction |
| 05/16/2001 | EP1098908A2 Anti-ccr2 antibodies and methods of use therefor |
| 05/16/2001 | EP1098898A1 Calcium (3s) tetrahydro-3-furanyl(1s,2r)-3- (4-aminophenyl) sulfonyl] (isobutyl) amino] -1-benzyl-2- (phosphonooxy) propylcarbamate |
| 05/16/2001 | EP1098886A1 Phthalazine derivatives as phosphodiesterase 4 inhibitors |
| 05/16/2001 | EP1098885A1 Imidazole compounds and their use as adenosine deaminase inhibitors |
| 05/16/2001 | EP1098884A1 Il-8 receptor antagonists |
| 05/16/2001 | EP1098873A1 Alpha-(2-hydroxyphenyl)nitrone compounds, pharmaceutical compositons containing the same and their use for treating inflammation |
| 05/16/2001 | EP1098870A2 Nitric esters and nitrate salts of specific drugs |
| 05/16/2001 | EP1084709A9 Oral recombinant lactobacilli vaccines |
| 05/16/2001 | EP0941089B1 Use of anti-microtubule agents for treating or preventing multiple sclerosis |
| 05/16/2001 | EP0859766B1 Chiral methyl phenyl oxazolidinones |
| 05/16/2001 | EP0842165B1 Thiazolidine-4-carboxylic acid derivatives as cytoprotective agents |
| 05/16/2001 | EP0810870B1 Isolated tumor rejection antigen precursor mage-2 derived peptides, and uses thereof |
| 05/16/2001 | CN1295571A PDE IV inhibiting pyridine derivatives |
| 05/16/2001 | CN1295564A HIV inhibiting pyrimidine derivatives |
| 05/16/2001 | CN1295548A Novel tricyclic compound |
| 05/16/2001 | CN1295483A Gelling ophthalmic composition containing xanthan gum |
| 05/16/2001 | CN1295482A Antagonists of the inflammatory mediator oncostatin M (OSM) |
| 05/16/2001 | CN1295471A Antagonists for treatment of CD11/CD18 adhesion receptor mediated disorders |
| 05/16/2001 | CN1295464A Solid, quick dissolving cetirizine fomulation |
| 05/16/2001 | CN1294911A Substituted nitrobenzene derivative for medicine and other use |
| 05/16/2001 | CN1065761C Anti-senility kindney invigorating health medicine and its preparing method |
| 05/16/2001 | CN1065751C Ledebouriella polysaccharide and its preparation |
| 05/16/2001 | CN1065748C Sea horse oral liquor and its preparing method |
| 05/15/2001 | US6232459 Synaptojanin isoform |
| 05/15/2001 | US6232454 Nucleic acid and amino acid sequences and use in diagnosis, treatment, and prevention of cancer and immune disorders |
| 05/15/2001 | US6232445 Soluble MHC complexes and methods of use thereof |
| 05/15/2001 | US6232441 PIGR-1, a member of immunoglobulin gene superfamily |
| 05/15/2001 | US6232321 Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
| 05/15/2001 | US6232300 Administering as hepatitis b viricide |
| 05/15/2001 | US6231893 Immunosuppressive and tumour-suppressive bone marrow factor |
| 05/15/2001 | US6231887 Drugs of pyranone derivatives |
| 05/15/2001 | US6231870 Oral administration of pneumoccal antigens |
| 05/15/2001 | US6231862 Purified new epididymal forward motility protein and a process for the isolation of the said epididymal forward motility protein useful as a fertility prometer/blocker |
| 05/15/2001 | US6231859 Saponin adjuvant compositions |
| 05/15/2001 | CA2041638C Recombinant polynucleotide constructs suitable for providing secretion of pai-2 |
| 05/15/2001 | CA1341231C Primary biliary cirrhosis autoantigen |
| 05/10/2001 | WO2001033221A1 Axor35, a g-protein coupled receptor |
| 05/10/2001 | WO2001032910A2 27 human secreted proteins |
| 05/10/2001 | WO2001032888A2 Human transferase molecules |
| 05/10/2001 | WO2001032877A2 CpG RECEPTOR (CpG-R) AND METHODS RELATING THERETO |
| 05/10/2001 | WO2001032867A1 Polypeptides with expanded primary signalling motifs |
| 05/10/2001 | WO2001032866A2 Hybrid adaptor receptors |
| 05/10/2001 | WO2001032865A1 Human gpr27-like g-protein coupled receptor polypeptide and polynucleotide sequences |
| 05/10/2001 | WO2001032841A2 Method of in vitro t cell differentiation of cd34+ progenitor cells |
| 05/10/2001 | WO2001032830A2 Process for producing, methods and compositions of glucuronoxylomannan as nutriceutical agent from higher basidiomycetes mushroom |
| 05/10/2001 | WO2001032709A2 Polypeptides with non-natural primary signalling motifs |
| 05/10/2001 | WO2001032696A2 Traf family proteins |
| 05/10/2001 | WO2001032690A1 Substituted dipeptides having nos inhibiting activity |
| 05/10/2001 | WO2001032687A1 10 human secreted proteins |
| 05/10/2001 | WO2001032680A2 18-nor-steroids as selectively active estrogens |
| 05/10/2001 | WO2001032677A1 Uteroglobin-like polynucleotides, polypeptides, and antibodies |
| 05/10/2001 | WO2001032676A1 25 human secreted proteins |
| 05/10/2001 | WO2001032675A1 32 human secreted proteins |
| 05/10/2001 | WO2001032674A1 26 human secreted proteins |
| 05/10/2001 | WO2001032667A1 Ether-type gla-60 analogues |
| 05/10/2001 | WO2001032658A1 Polyazanaphthalene compound and medicinal use thereof |
| 05/10/2001 | WO2001032654A2 Novel heterocyclic compounds and their use as medicines |
| 05/10/2001 | WO2001032653A1 Heterocyclic substituted pyrazolones |
| 05/10/2001 | WO2001032650A2 Alkaline salts of n-(6-alkyl-2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinesulfone)-n'-isonicotinoylhydrazide, possess for their preparation, and pharmaceutical composition based on these salts |
| 05/10/2001 | WO2001032649A1 Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof |